An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Summary

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Timeline

Start

2018-04-11

Primary completion

2019-05-31

Completion

2019-05-31

Outcome

Outcome not reported

Stopped: “This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”

Drugs

Indications